4,171 Shares in TransMedics Group, Inc. $TMDX Purchased by Envestnet Portfolio Solutions Inc.

Key Points

• Envestnet Portfolio Solutions Inc. purchased 4,171 shares of TransMedics Group, valued at approximately $559,000, during the second quarter, reflecting growing institutional interest in the company.
• Analysts have varying opinions on TransMedics Group, with ratings ranging from "hold" to "buy" and target prices spanning $115.00 to $155.00, indicating a generally positive sentiment towards the stock.
• TransMedics Group reported strong quarterly earnings, with $0.92 EPS and a year-over-year revenue increase of 37.7%, exceeding analysts' expectations and showcasing its solid growth potential.

Envestnet Portfolio Solutions Inc. bought a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 4,171 shares of the company's stock, valued at approximately $559,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. OneDigital Investment Advisors LLC raised its stake in TransMedics Group by 52.6% in the 1st quarter. OneDigital Investment Advisors LLC now owns 5,989 shares of the company's stock worth $403,000 after purchasing an additional 2,065 shares in the last quarter. Principal Financial Group Inc. raised its stake in TransMedics Group by 2.8% in the 1st quarter. Principal Financial Group Inc. now owns 198,427 shares of the company's stock worth $13,350,000 after purchasing an additional 5,480 shares in the last quarter. Vontobel Holding Ltd. acquired a new stake in TransMedics Group in the 1st quarter worth about $291,000. New York State Teachers Retirement System raised its stake in TransMedics Group by 183.2% in the 1st quarter. New York State Teachers Retirement System now owns 21,949 shares of the company's stock worth $1,477,000 after purchasing an additional 14,200 shares in the last quarter. Finally, Peregrine Capital Management LLC raised its stake in TransMedics Group by 3.4% in the 1st quarter. Peregrine Capital Management LLC now owns 68,390 shares of the company's stock worth $4,601,000 after purchasing an additional 2,250 shares in the last quarter. Institutional investors own 99.67% of the company's stock.

Analysts Set New Price Targets

Several brokerages have recently commented on TMDX. Stifel Nicolaus began coverage on shares of TransMedics Group in a research report on Thursday, September 4th. They issued a "hold" rating and a $115.00 target price for the company. Jefferies Financial Group began coverage on shares of TransMedics Group in a research report on Monday, October 13th. They issued a "buy" rating and a $145.00 target price for the company. Needham & Company LLC restated a "hold" rating on shares of TransMedics Group in a research report on Monday, August 25th. Wall Street Zen upgraded shares of TransMedics Group from a "hold" rating to a "buy" rating in a research report on Saturday. Finally, Evercore ISI began coverage on shares of TransMedics Group in a research report on Tuesday, September 16th. They issued an "outperform" rating and a $155.00 target price for the company. Seven equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, TransMedics Group has a consensus rating of "Moderate Buy" and an average target price of $127.18.

TransMedics Group Trading Up 0.2%

Shares of NASDAQ TMDX opened at $120.13 on Wednesday. The company has a debt-to-equity ratio of 1.61, a quick ratio of 9.17 and a current ratio of 9.86. TransMedics Group, Inc. has a 52-week low of $55.00 and a 52-week high of $145.50. The firm has a 50 day moving average price of $116.15 and a two-hundred day moving average price of $114.35. The stock has a market cap of $4.10 billion, a P/E ratio of 62.24 and a beta of 2.08.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.44. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The firm had revenue of $157.37 million during the quarter, compared to analysts' expectations of $146.64 million. During the same period in the prior year, the company posted $0.35 EPS. The company's revenue was up 37.7% on a year-over-year basis. TransMedics Group has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.